NYU Langone Health
New York, 10016, United States
Location status: Recruiting
NCT Number: NCT07449091
Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fear of transmission to their partners leading to social isolation and impact on their personal lives. This study will provide data correlating serum and body fluid viral levels in persons with chronic hepatitis B infection not on therapy and those with viral suppression on long-term anti-retroviral therapy (ART) that may support the concept of "Undetectable=Untransmissible" (U=U) in patients with chronic hepatitis B.
Interested in participating?
Request Info18 year–65 year
All sexes
Observational
New York, 10016, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Infected Individuals
Healthy Controls
Exclusion criteria
Time frame: Up to Month 6
Assessed among those who have achieved viral supression.
Time frame: Up to Month 6
Assessed among those with detectable HBV DNA.
Contact information is provided by the study sponsor or research team.
NYU Langone Health
Other
Adaptability of an Undetectable = Untransmissible Model for HBV: Are Suppressed Viral Levels in the Serum Consistent Across Body Fluid Reservoirs?
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06092333
Blood-Borne Infections, Chronic Disease
Bethesda, Maryland, United States
View Trial DetailsNCT07709520
Blood-Borne Infections, Chronic Disease
Beijing, China
View Trial DetailsNCT07573943
Blood-Borne Infections, Chronic Disease
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT06638320
Blood-Borne Infections, Chronic Disease
Hà Nội, Northern Vietnam, Vietnam
View Trial Details